Tralokinumab

Drug Profile

Tralokinumab

Alternative Names: CAT-354

Latest Information Update: 26 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cambridge Antibody Technology
  • Developer Icahn School of Medicine at Mount Sinai; LEO Pharma; MedImmune
  • Class Antiasthmatics; Antifibrotics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 13 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Asthma; Atopic dermatitis
  • Phase II Alopecia areata
  • Discontinued Chronic obstructive pulmonary disease; Idiopathic pulmonary fibrosis; Ulcerative colitis

Most Recent Events

  • 21 Sep 2017 AstraZeneca completes a phase III trial in Asthma (In adults, In adolescents) in USA, Canada, Chile, Mexico, Japan, Philippines, South Africa, United Kingdom, Czech Republic, Italy, Russia, Taiwan, Poland and Ukraine (NCT02194699) (EudraCT2013-005615-27)
  • 07 Sep 2017 AstraZeneca completes a phase III trial for Asthma (In adolescents, In adults) in Belgium, USA, France, Germany, Poland, Ukarine and Netherlands (SC) (NCT02281357)
  • 07 Aug 2017 AstraZeneca completes a phase III trial For Asthma (In adolescents, In adults, Treatment-experienced) in USA, Germany, Hungary, Poland, Slovakia, Spain, Argentina, Belgium, Bulgaria, Colombia, Peru, Vietnam, Ukraine and Taiwan (NCT02161757)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top